Chest
-
Comorbidities of OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Type 2 diabetes mellitus (DM) and obstructive sleep apnea (OSA) share clinical outcomes being in this way a major public health concern. OSA may be under-recognised comorbidity of DM, so recent reports have indicated that the majority of patients with type 2 diabetes also have obstructive sleep apnea syndrome (OSA). The aim of the study was to evaluate the presence of diabetes mellitus between patients with obstructive sleep apnea syndrome. ⋯ The following authors have nothing to disclose: Doina Adina Todea, Paraschiva Postolache, Andreea Codruta Coman, Loredana Elena RoscaNo Product/Research Disclosure Information.
-
Respiratory InfectionsSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The treatment of XDR-TB is less effective than that of other forms of TB because of the lack of efficacious anti-TB drugs so that the infection is frequently fatal. To investigate the efficacy and safety of linezolid containing chemotherapy in patients with XDR-TB in China. ⋯ The following authors have nothing to disclose: Shenjie Tang, Lan Yao, Xiaohui Hao, Xia Zhang, Gang Liu, Xin Liu, Meiying Wu, Linhai Zeng, Hua Sun, Yidian Liu, Jin Gu, Feishen Lin, Xiafang Wang, Zhanjun ZhangNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The IGNITE program investigated the efficacy and safety of dual bronchodilation with once-daily QVA149 [fixed-dose combination of indacaterol (long-acting β2-agonist) and glycopyrronium (long-acting muscarinic antagonist)] for the treatment of patients with moderate-to-severe COPD. ⋯ Karen Mezzi: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Pulmonary and Sleep MedicineSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Routine manometry has been advocated to prevent complications during therapeutic thoracentesis, but has not convincingly been shown to prevent pneumothorax ex vacuo or re-expansion pulmonary edema. As chest pain is correlated with negative pleural pressures, we aimed to determine whether the use of manometry could be associated with less pain during therapeutic thoracentesis. ⋯ The following authors have nothing to disclose: Jasleen Pannu, Zachary DePew, John Mullon, Craig Daniels, Clinton Hagen, Fabien MaldonadoNo Product/Research Disclosure Information.
-
Cardiovascular Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Acute myocarditis is a clinical condition commonly encountered in Portugal in the winter season. As markers of cardiac necrosis are commonly elevated with symptoms resembling acute coronary syndromes with equivocal ECG alterations, patients undergo coronary angiography routinely. The advent of cardiac MRI with the formulation of the Lake Louise criteria has allowed for a diagnosis of acute myocarditis. The aim of the study was to audit the decision to use of coronary angiography in patients diagnosed clinically with acute myocarditis. The decision was left to the treating physician. ⋯ The following authors have nothing to disclose: Dinis Mesquita, Carla Nobre, Boban ThomasNo Product/Research Disclosure Information.